Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
OXD01 + buprenorphine + naloxone
- Development stage
- Unknown
- Lead developer
- Orexo
- Modality
- Small Molecules
- Administration
- Sublingual
01
Overview
OXD01 + buprenorphine + naloxone refers specifically to the combination of a **digital therapeutic (OXD01, also known as MODIA)** with sublingual **buprenorphine/naloxone**, as studied in clinical trials for opioid use disorder. OXD01 is a device-based digital psychotherapy intervention grounded in cognitive behavioral therapy and motivational interviewing, designed to support individuals diagnosed with opioid use disorder by augmenting medication-assisted treatment. Buprenorphine is a partial agonist at the mu-opioid receptor, helping manage opioid withdrawal and cravings, while naloxone is an opioid receptor antagonist added to deter abuse by precipitating withdrawal if injected. This combined product is investigated for its ability to reduce opioid use more effectively than medication alone as part of a comprehensive treatment plan including counseling and behavioral therapy.
- Other names
- MODIA + buprenorphine + naloxone
02
Targets
NOP (Nociceptin/orphanin FQ peptide receptor)MOR (Mu opioid receptor)DOR (Opioid Receptor Delta 1)KOR (Kappa opioid receptor)
Beyond the preview
Go deeper on OXD01 + buprenorphine + naloxone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on OXD01 + buprenorphine + naloxone.